Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate at other companies

Norwood Financial logo
Norwood FinancialNWFL
4.5%0.0pp
CHE
ChemedCHE
0.5%+0.2pp
Belden logo
BeldenBDC
0.2%-0.1pp
RBC Bearings logo
RBC BearingsRBC
0%—
Quantum Computing Inc. logo
Quantum Computing Inc.QUBT
0%—
Capital City Bank Group logo
Capital City Bank GroupCCBG
2.6%-0.4pp

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award fair value assumptions expected dividend rate.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award fair value assumptions expected dividend rate?
Relmada Therapeutics, Inc. (RLMD) reported share based compensation arrangement by share based payment award fair value assumptions expected dividend rate of 0% in Q4 2025.